Lantheus Weighs $7 Billion Sale After Curium Takeover Approach

Radiopharmaceutical company Lantheus Holdings is actively exploring a potential sale after receiving a takeover approach that would value the business at roughly $7 billion, Yahoo! Finance Canada reported Friday. The offer came from Curium Pharma, a private-equity-backed nuclear medicine specialist with a comparable valuation of its own.

Deal Talks Could Close Within Weeks

According to the report, discussions between Lantheus and Curium are ongoing and may reach a conclusion in a matter of weeks. Neither company has confirmed the negotiations publicly. Yahoo! Finance Canada noted that no final agreement has been reached, and a completed transaction is far from certain. Both Lantheus and Curium declined to comment when contacted.

Also Read: What the Novo Nordisk-Catalent Deal Means for Pharma Manufacturing

Who Is Curium and What Is CapVest

Curium is not a household name outside specialist medical circles, but its backers carry serious weight. Private equity firm CapVest Partners owns the nuclear medicine company. CapVest raised capital through a continuation vehicle for Curium last year, at which point the business was already pegged at around $7 billion. Continuation vehicles allow PE sponsors to hold assets longer while offering liquidity to existing investors. The structure signals CapVest’s confidence in Curium’s long-term growth trajectory.

Also Read: Private Equity Continuation Funds Explained

Lantheus Stock Has Surged in 2026

Lantheus shares slipped nearly 2% in after-hours trading following the report, a modest pullback after a standout run. The stock has climbed nearly 55% since January, pushing the company’s market capitalisation to approximately $6.15 billion before the news broke. That strong performance reflects growing investor appetite for radiopharmaceutical platforms. The sector has attracted intense deal activity as large drugmakers seek exposure to targeted cancer therapies that use radioactive compounds for both diagnosis and treatment.

Radiopharma M&A Has Heated Up

The Lantheus-Curium talks fit a broader pattern of consolidation in nuclear medicine. Major pharmaceutical groups have moved aggressively to acquire radiopharmaceutical assets over the past two years. Bristol Myers Squibb, Eli Lilly, and others have all committed significant capital to the space, driving up valuations across the board. A Lantheus sale at $7 billion would rank among the larger transactions in the segment and would underscore how quickly the sector has moved from niche to mainstream.

Read Next: Pharma M&A Watch: The Deals Shaping Drug Discovery in 2026